It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. About the AbbVie, Inc. stock forecast. Trading CFDs is high risk and is not suitable for everyone. As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. AbbVie's Dividend and Valuation. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Within the oncology division sales of Imbruvica fell 17% year-on-year. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. I wrote this article myself, and it expresses my own opinions. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. As we can see above one of either Skyrizi or Rinvoq has now been approved for all of the same indications as Humira is, except for Hidradenitis Suppurativa, although Rinvoq is undergoing a Phase study in this indication. The average price target represents a 6.33% change from the last price of $153.90. Build a CFD portfolio with your favourite companies. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. The major market events for the week ahead right in your inbox. Please disable your ad-blocker and refresh. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. I'm on twitter @edmundingham. Please log in to your account or sign up in order to add this asset to your watchlist. If you have an ad-blocker enabled you may be blocked from proceeding. 16 analysts have issued 12-month price targets for AbbVie's shares. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. CNN Sans & 2016 Cable News Network. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. Always conduct your own due diligence before investing. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . Rinvoq's progress has been a little more circumspect, but almost as impressive. According to the Abbvie stock technical analysis, as of 30 June, the Relative Strength Index (RSI) was pointing to neutral at 62.18. After 2022 Humira's row is shaded yellow to signify patent expiry. AbbVie has received a consensus rating of Hold. The analysts 12-month consensus ABBV stock price target was $159.75. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. If you have an ad-blocker enabled you may be blocked from proceeding. Payout ratios above 75% are not desirable because they may not be sustainable. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. AbbVie passed that onto its 2022 guidance. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Having so much debt in a prevailing inflationary environment is also unattractive. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. 326 E 8th St #105, Sioux Falls, SD 57103 AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Shares of ABBV stock can be purchased through any online brokerage account. Pharmaceuticals are often valued based on a philosophy of "jam tomorrow" as opposed to jam today i.e. The eye-disease markets are very large - Regeneron's Eylea is a >$7bn per annum selling drug and AMD markets are >$20bn in size. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. A Warner Bros. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Only you can design whether Abbvie stock is the right investment for you. Factset: FactSet Research Systems Inc.2019. . 1 dividend stock for a LIFETIME of income. The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. This means that . (my tables and forecasting). In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. In February, a Phase 3 induction study saw positive top-line results. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. The Abbvie stock forecast for 2025 had the price at $259.018. AbbVie is a leading dividend payer. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. Investors needn't panic however - Humira's replacements are expected by AbbVie's CEO to generate even higher revenues per annum. Please. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. High institutional ownership can be a signal of strong market trust in this company. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. (844) 978-6257. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. On average, they expect the company's stock price to reach $161.12 in the next twelve months. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. On average, analysts rate AbbVie stock as a buy. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. My No. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. Payout ratios above 75% are not desirable because they may not be sustainable. I'm on twitter @edmundingham. According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. ABBV has several positive factors pushing its price performance. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. To summarize, although AbbVie does not have the same clout in oncology as it does in immunology - as evidenced perhaps by the declining sales of Imbruvica - it is clearly an area of focus for management. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. I wrote this article myself, and it expresses my own opinions. Their ABBV share price forecasts range from $140.00 to $200.00. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. AbbVie has a PEG Ratio of 3.51. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). What is Richard A. Gonzalez's approval rating as AbbVie's CEO? My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. View the best growth stocks for 2023 here. As such, forecasting stock prices is more of an art than a science. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. What guidance has AbbVie issued on next quarter's earnings? I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. . To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Retail sales were up but so was inflation which meant more volatility for stocks. Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. As we can see the immunology division consists of only 3 assets yet by my calculation, will likely account for 50% of AbbVie's revenues in 2022 (to calculate 2022 sales revenues by product, since we do not yet have final figures, I have used 9m 2022 figures and assumed Q4 revenues will be the average of the previous 3 quarters). In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. I am not receiving compensation for it (other than from Seeking Alpha). See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. I wrote this article myself, and it expresses my own opinions. Your current $100 investment may be up to $188.28 in 2028. The surge in revenues can primarily be attributed to its Allergan. 2022 Cable News Network. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. AbbVie income statement forecast (My table and assumptions). Sign in to your free account to enjoy all that MarketBeat has to offer. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. Refer to our. As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. Skyrizi - which inhibits the activities of IL-23 - a naturally occurring cytokine that is involved in inflammatory and immune responses - and Rinvoq - a member of the janus kinase inhibitor drug class - fit this profile. View ABBV analyst ratings or view top-rated stocks. The pharma industry witnessed solid growth amid the pandemic. It now expects full-year profit in the range of $13.92-$14.12 a share. I have no business relationship with any company whose stock is mentioned in this article. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. I have no business relationship with any company whose stock is mentioned in this article. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Teliso V is an antibody drug conjugate and a c-Met inhibitor. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. AbbVie (NYSE:ABBV) has a market capitalization of $276.13 billion and generates $58.05 billion in revenue each year. Real-time analyst ratings, insider transactions, earnings data, and more. Zscaler, Inc Plummets, Is It Time To Buy The Dip? The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. AbbVie has 5 focus areas for its research and products. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. Since then, however, the stock price has fallen 18% to its current price of $142.6. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Read our dividend analysis for ABBV. As such I have modelled similar, although I have included an additional revenue stream from new products which I expect to be minor in nature but ultimately contributing an additional $1.5bn to the top line. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Enjoy your holiday weekend and catch up on our most read stories this week. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Forecast . The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. Should I buy or sell AbbVie stock right now? call (03) 8658 0539 support.au@capital.com. (my table and forecasts). AbbVie declared a quarterly dividend on Thursday, February 16th. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. For the next eight years, the forecast is for Free Cash Flow to grow by . All rights reserved. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. AbbVie discounted cash flow analysis. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. In general, it is important to pay attention to trends, both in the overall market and in the specific sector that a company is in. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. Different trading strategies will suit different investment goals with short or long-term focus. Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. AbbVie has been increasing its dividend for 51 years. This suggests a possible upside of 3.2% from the stock's current price. Read our dividend analysis for ABBV. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. Slide from JPM Conference 2022 presentation. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. I am not receiving compensation for it (other than from Seeking Alpha). The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. These are Immunology, Oncology, Neurology, Virology and Eye Care. View which stocks are hot on social media with MarketBeat's trending stocks report. Date. Over the years, AbbView Inc. has made numerous acquisitions. On average, they predict the company's stock price to reach $161.12 in the next year. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. AbbVie Inc. is a US-based biopharma company with global operations. AbbVie Inc. (NYSE:ABBV) posted its earnings results on Thursday, February, 9th. PEG Ratios above 1 indicate that a company could be overvalued. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. Disclaimer. Investors are already flocking there for a chance at 1,000%+ returns. Always do your own research on a stocks price performance and predictions before making an investment. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market.
